The era of lenalidomide maintenance therapy in multiple myeloma: settings for achieving best outcomes

References

• Gupta D, Treon SP, Shima Y, et al. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia. 2001 Dec;15(12):1950–1961.
   Google Scholar
• Breitkreutz I, Raab MS, Vallet S, et al. Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma. Leukemia. 2008 Oct;22(10):1925–1932.
   Google Scholar
• Bolzoni M, Storti P, Bonomini S, et al. Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and the RANKL/OPG ratio in the myeloma microenvironment targeting the expression of adhesion molecules. Exp Hematol. 2013 Apr;41(4):387–97.e1.
   Google Scholar
• Corral LG, Haslett PA, Muller GW, et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol. [1999 Jul 1];163(1):380–386.
   Google Scholar
• LeBlanc R, Hideshima T, Catley LP, et al. Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. Blood. [2004 Mar 1];103(5):1787–1790.
   Google Scholar
• Henry JY, Labarthe MC, Meyer B, et al. Enhanced cross-priming of naive CD8+ T cells by dendritic cells treated by the IMiDs(R) immunomodulatory compounds lenalidomide and pomalidomide. Immunology. 2013 Jul;139(3):377–385.
   Google Scholar
• Chang DH, Liu N, Klimek V, et al. Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. Blood. [2006 Jul 15];108(2):618–621.
   Google Scholar
• Zhu D, Corral LG, Fleming YW, et al. Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation. Cancer Immunol Immunother. 2008 Dec;57(12):1849–1859.
   Google Scholar
• Gorgun G, Calabrese E, Soydan E, et al. Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma. Blood. [2010 Oct 28];116(17):3227–3237.
   Google Scholar
• Galustian C, Meyer B, Labarthe MC, et al. The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunol Immunother. 2009 Jul;58(7):1033–1045.
   Google Scholar
• Ito T, Ando H, Suzuki T, et al. Identification of a primary target of thalidomide teratogenicity. Science. [2010 Mar 12];327(5971):1345–1350.
   Google Scholar
• Zhu YX, Braggio E, Shi CX, et al. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood. [2011 Nov 3];118(18):4771–4779.
   Google Scholar
• Liu Y, Huang X, He X, et al. A novel effect of thalidomide and its analogs: suppression of cereblon ubiquitination enhances ubiquitin ligase function. FASEB J. 2015 Dec;29(12):4829–4839.
   Google Scholar
• Zhu YX, Braggio E, Shi CX, et al. Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma. Blood. [2014 Jul 24];124(4):536–545.
   Google Scholar
• Kronke J, Udeshi ND, Narla A, et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science. [2014 Jan 17];343(6168):301–305.
   Google Scholar
• Lu G, Middleton RE, Sun H, et al. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science. [2014 Jan 17];343(6168):305–309.
   Google Scholar
• Morgan B, Sun L, Avitahl N, et al. Aiolos, a lymphoid restricted transcription factor that interacts with Ikaros to regulate lymphocyte differentiation. EMBO J. [1997 Apr 15];16(8):2004–2013.
   Google Scholar
• Cortes M, Georgopoulos K. Aiolos is required for the generation of high affinity bone marrow plasma cells responsible for long-term immunity. J Exp Med. 2004 Jan 19;199(2):209–219.
   Google Scholar
• Xin W, Xiaohua N, Peilin C, et al. Primary function analysis of human mental retardation related gene CRBN. Mol Biol Rep. 2008 Jun;35(2):251–256.
   Google Scholar
• Lee J, Zhou P. DCAFs, the missing link of the CUL4-DDB1 ubiquitin ligase. Mol Cell. 2007 Jun 22;26(6):775–780.
   Google Scholar
• Schuster SR, Kortuem KM, Zhu YX, et al. The clinical significance of cereblon expression in multiple myeloma. Leuk Res. 2014 Jan;38(1):23–28.
   Google Scholar
• Chen N, Wen L, Lau H, et al. Pharmacokinetics, metabolism and excretion of [(14)C]-lenalidomide following oral administration in healthy male subjects. Cancer Chemother Pharmacol. 2012 Mar;69(3):789–797.
   Google Scholar
• Chen N, Zhou S, Palmisano M. Clinical Pharmacokinetics and Pharmacodynamics of Lenalidomide. Clin Pharmacokinet. 2017 Feb;56(2):139–152.
   Google Scholar
• Revlimid prescribing information. United States Food and Drug Administration; 2017.
   Google Scholar
• Nojkov B, Signori C, Konda A, et al. Lenalidomide-associated hepatotoxicity–a case report and literature review. Anticancer Res. 2012 Sep;32(9):4117–4119.
   Google Scholar
• Palumbo A, Gay F, Falco P, et al. Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients. J Clin Oncol. [2010 Feb 10];28(5):800–807.
   Google Scholar
• McCarthy PL, Owzar K, Hofmeister CC, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med. [2012 May 10];366(19):1770–1781.
   Google Scholar
• Holstein SA, Jung SH, Richardson PG, et al. Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial. Lancet Haematol. 2017 Sep;4(9):e431–e42.
   Google Scholar
• Attal M, Lauwers-Cances V, Marit G, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med. [2012 May 10];366(19):1782–1791.
   Google Scholar
• Palumbo A, Cavallo F, Gay F, et al. Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med. [2014 Sep 4];371(10):895–905.
   Google Scholar
• Jackson GH, Davies FE, Pawlyn C, et al. Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2019 Jan;20(1):57–73. *This study provided evidence of PFS benefit of lenalidomide maintenance regardless of cytogenetic risk
   Google Scholar
• McCarthy PL, Holstein SA, Petrucci MT, et al. Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: a Meta-Analysis. J Clin Oncol. 2017 Oct 10;35(29):3279–3289.**This meta-analysis provided evidence of overall survival benefit of lenalidomide maintenance.
   Google Scholar
• Bonello F, Pulini S, and Ballanti S, et al. Lenalidomide Maintenance with or without Prednisone in Newly Diagnosed Myeloma Patients: a Pooled Analysis. Cancers (Basel). 2019 Nov 5;11(11): 1735.
   Google Scholar
• Sharma N, Chen DT, Zhao Q, et al. Lenalidomide and Vorinostat Maintenance after Autologous Transplantation in Multiple Myeloma: long- Term Follow-Up. Biol Blood Marrow Transplant. 2020 Jan;26(1):44–49.
   Google Scholar
• Jenner M, Striha A, and Davies F, et al. Addition of vorinostat to lenalidomide maintenance in newly diagnosed myeloma does not improve outcomes: results of the Myeloma XI trial. European Hematology Association 2018 Stockholm, Sweden. p. 586
   Google Scholar
• Goldschmidt H, Mai EK, Bertsch U, et al. Elotuzumab in Combination with Lenalidomide, Bortezomib, Dexamethasone and Autologous Transplantation for Newly-Diagnosed Multiple Myeloma: results from the Randomized Phase III GMMG-HD6 Trial. Blood. 2021;138(Supplement 1):486.
   Google Scholar
• Usmani SZ, Hoering A, Ailawadhi S, et al. Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial. Lancet Haematol. 2021 Jan;8(1):e45–e54.
   Google Scholar
• Voorhees PM, Kaufman JL, Laubach J, et al. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood. [2020 Aug 20];136(8):936–945.
   Google Scholar
• Kaufman JL, Laubach JP, Sborov D, et al. Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): updated Analysis of Griffin after 12 Months of Maintenance Therapy. Blood. 2020;136(Supplement 1):45–46.
   Google Scholar
• Krishnan A, Hoering A, Hari P, et al. Phase III Study of Daratumumab/rhuph20 (nsc- 810307) + Lenalidomide or Lenalidomide As Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (mm) Using Minimal Residual Disease To direct Therapy Duration (DRAMMATIC study): SWOG s1803. Blood. 2020;136(Supplement 1):21–22.
   Google Scholar
• Nooka AK, Kaufman JL, Muppidi S, et al. Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients. Leukemia. 2014 Mar;28(3):690–693.
   Google Scholar
• Joseph NS, Kaufman JL, Dhodapkar MV, et al. Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma. J Clin Oncol. [2020 Jun 10];38(17):1928–1937.
   Google Scholar
• Patel KK, Shah JJ, Feng L, et al. Update on a Phase II Study of Ixazomib with Lenalidomide As Maintenance Therapy Following Autologous Stem Cell Transplant in Patients with Multiple Myeloma. Blood. 2017;130(Supplement 1):437.
   Google Scholar
• Paiva B, Puig N, Cedena MT, et al. Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma. J Clin Oncol. [2020 Mar 10];38(8):784–792.
   Google Scholar
• Rosinol L, Oriol A, Ríos Tamayo R, et al. Ixazomib Plus Lenalidomide/Dexamethasone (IRd) Versus Lenalidomide /Dexamethasone (Rd) Maintenance after Autologous Stem Cell Transplant in Patients with Newly Diagnosed Multiple Myeloma: results of the Spanish GEM2014MAIN Trial. Blood. 2021;138(Supplement 1):466. *This randomized study failed to show benefit of adding ixaxomib to lenalidomide/dexamethasone maintenance
   Google Scholar
• Gay F, Musto P, and Rota-Scalabrini D, et al. Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial. Lancet Oncol 2021, 22(12): 1705–1720. 2021.** This randomized study demonstrated PFS benefit of adding carfilzomib to lenalidomide maintenance.
   Google Scholar
• Ludwig H, Boccadoro M, Moreau P, et al. Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network. Leukemia. 2021 Jan;35(1):31–44.
   Google Scholar
• Hahn M, Schnitzler P, Schweiger B, et al. Efficacy of single versus boost vaccination against influenza virus in patients with multiple myeloma. Haematologica. 2015 Jul;100(7):e285–8.
   Google Scholar
• Terpos E, Trougakos IP, Gavriatopoulou M, et al. Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose. Blood. [2021 Jul 1];137(26):3674–3676.
   Google Scholar
• Van Oekelen O, Gleason CR, Agte S, et al. Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma. Cancer Cell. [2021 Aug 9];39(8):1028–1030.
   Google Scholar
• Pimpinelli F, Marchesi F, Piaggio G, et al. Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution. J Hematol Oncol. [2021 May 17];14(1):81.
   Google Scholar
• Pawlyn C, Khan MS, Muls A, et al. Lenalidomide-induced diarrhea in patients with myeloma is caused by bile acid malabsorption that responds to treatment. Blood. [2014 Oct 9];124(15):2467–2468.
   Google Scholar
• Palumbo A, Rajkumar SV, Dimopoulos MA, et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia. 2008 Feb;22(2):414–423.
   Google Scholar
• Nardone B, Wu S, Garden BC, et al. Risk of rash associated with lenalidomide in cancer patients: a systematic review of the literature and meta-analysis. Clin Lymphoma Myeloma Leuk. 2013 Aug;13(4):424–429.
   Google Scholar
• Barley K, He W, Agarwal S, et al. Outcomes and management of lenalidomide-associated rash in patients with multiple myeloma. Leuk Lymphoma. 2016 Nov;57(11):2510–2515.
   Google Scholar
• Tinsley SM, Kurtin SE, Ridgeway JA. Practical Management of Lenalidomide-Related Rash. Clin Lymphoma Myeloma Leuk. 2015 Jun;15:S64–9.
   Google Scholar
• Lee MJ, Wickner P, Fanning L, et al. Lenalidomide desensitization for delayed hypersensitivity reactions in 5 patients with multiple myeloma. Br J Haematol. 2014 Oct;167(1):127–131.
   Google Scholar
• Abonour R, Durie BGM, Jagannath S, et al. Health-Related Quality of Life of Patients with Newly Diagnosed Multiple Myeloma Receiving Any or Lenalidomide Maintenance after Autologous Stem Cell Transplant in the Connect® MM Disease Registry. Blood. 2016;128(22):537.
   Google Scholar
• Boquoi A, Giagounidis A, Goldschmidt H, et al. Similar Quality of Life with 5mg Versus 25mg Lenalidomide Maintenance after First-Line High-Dose Therapy and Autologous Blood Stem Cell Transplantation for Multiple Myeloma: results of the Lenamain Trial. Blood. 2018;132(Supplement 1):2003.
   Google Scholar
• Roussel M, Hebraud B, Hulin C, et al. Health-related quality of life results from the IFM 2009 trial: treatment with lenalidomide, bortezomib, and dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma. Leuk Lymphoma. 2020 Jun;61(6):1323–1333.
   Google Scholar
• Hari P, Ung B, Abouzaid S, et al. Lenalidomide maintenance post-transplantation in newly diagnosed multiple myeloma: real-world outcomes and costs. Future Oncol. 2019 Dec;15(35):4045–4056.
   Google Scholar
• Jagannath S, Abonour R, Durie BGM, et al. Impact of post-ASCT maintenance therapy on outcomes in patients with newly diagnosed multiple myeloma in Connect MM. Blood Adv. [2018 Jul 10];2(13):1608–1615.
   Google Scholar
• Jaiswal S, Fontanillas P, Flannick J, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. [2014 Dec 25];371(26):2488–2498.
   Google Scholar
• Mouhieddine TH, Sperling AS, Redd R, et al. Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant. Nat Commun. [2020 Jun 12];11(1):2996.
   Google Scholar
• Ho M, Zanwar S, Kapoor P, et al. The Effect of Duration of Lenalidomide Maintenance and Outcomes of Different Salvage Regimens in Patients with Multiple Myeloma (MM). Blood Cancer J. [2021 Sep 22];11(9):158.
   Google Scholar
• Stadtmauer EA, Pasquini MC, Blackwell B, et al. Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: results of the BMT CTN 0702 Trial. J Clin Oncol. [2019 Mar 1];37(7):589–597.
   Google Scholar
• Hari P, Pasquini MC, Stadtmauer EA, et al. Long-term follow-up of BMT CTN 0702 (STaMINA) of postautologous hematopoietic cell transplantation (autoHCT) strategies in the upfront treatment of multiple myeloma (MM). J Clin Oncol. 2020;38(15_suppl):8506.
   Google Scholar
• Avet-Loiseau H, Ludwig H, Landgren O, et al. Minimal Residual Disease Status as a Surrogate Endpoint for Progression-free Survival in Newly Diagnosed Multiple Myeloma Studies: a Meta-analysis. Clin Lymphoma Myeloma Leuk. 2020 Jan;20(1):e30–e7.
   Google Scholar
• Munshi NC, Avet-Loiseau H, Rawstron AC, et al. Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: a Meta-analysis. JAMA Oncol. [2017 Jan 01];3(1):28–35.
   Google Scholar
• Paiva B, Vidriales MB, Cervero J, et al. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood. [2008 Nov 15];112(10):4017–4023.
   Google Scholar
• Rawstron AC, Child JA, de Tute RM, et al. Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study. J Clin Oncol. [2013 Jul 10];31(20):2540–2547.
   Google Scholar
• Holstein SA, Al-Kadhimi Z, Costa LJ, et al. Summary of the Third Annual Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling. Biol Blood Marrow Transplant. 2020 Jan;26(1):e7–e15.
   Google Scholar
• Hahn TE, Wallace PK, Fraser R, et al. Minimal Residual Disease (MRD) Assessment before and after Autologous Hematopoietic Cell Transplantation (AutoHCT) and Maintenance for Multiple Myeloma (MM): results of the Prognostic Immunophenotyping for Myeloma Response (PRIMeR) Study. Biol Blood Marrow Transplant. 2019 ;25(3):S4–S6. 2019/03/01/.
   Google Scholar
• Attal M, Lauwers-Cances V, Hulin C, et al. Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma. N Engl J Med. [2017 Apr 06];376(14):1311–1320.
   Google Scholar
• Perrot A, Lauwers-Cances V, Corre J, et al. Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. Blood. [2018 Dec 6];132(23):2456–2464.
   Google Scholar
• Cavo M, Gay F, Beksac M, et al. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study. Lancet Haematol. 2020 Jun;7(6):e456–e68.
   Google Scholar
• Oliva S, Bruinink DHO, Rihova L, et al. Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial. Blood Cancer J. [2021 Jun 3];11(6):106.
   Google Scholar
• De Tute R, Cairns D, Rawstron A, et al. Sequential minimal residual disease (MRD) monitoring: results from the UK Myeloma XI trial. Clin Lymphoma Myeloma Leuk. 2019;19(10):e45–e6.
   Google Scholar
• Diamond B, Korde N, Lesokhin AM, et al. Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial. Lancet Haematol. 2021 Jun;8(6):e422–e32.
   Google Scholar
• Usmani SZ, Garfall AL, van de Donk N, et al. Teclistamab, a B-cell maturation antigen x CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study. Lancet. [2021 Aug 21];398(10301):665–674.
   Google Scholar
• Berdeja JG, Krishnan AY, Oriol A, et al. Updated results of a phase 1, first-in-human study of talquetamab, a G protein-coupled receptor family C group 5 member D (GPRC5D) × CD3 bispecific antibody, in relapsed/refractory multiple myeloma (MM). J Clin Oncol. 2021;39(15_suppl):8008.
   Google Scholar
• Cohen AD, Harrison SJ, Krishnan A, et al. Initial Clinical Activity and Safety of BFCR4350A, a FcRH5/CD3 T-Cell-Engaging Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma. Blood. 2020;136(Supplement 1):42–43.
   Google Scholar
• Lonial S, NWCJvd D, Popat R, et al. First clinical (phase 1b/2a) study of iberdomide (CC-220; IBER), a CELMoD, in combination with dexamethasone (DEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM). J Clin Oncol. 2019;37(15_suppl):8006.
   Google Scholar
• Wong L, Lamba M, Jiménez Nuñez MD, et al. Dose- and Schedule-Dependent Immunomodulatory Effects of the Novel Celmod Agent CC-92480 in Patients with Relapsed/Refractory Multiple Myeloma. Blood. 2020;136(Supplement 1):47–48.
   Google Scholar